Literature DB >> 8819013

Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

P W Brandt-Rauf1, J M Chen, M J Marion, S J Smith, J C Luo, W Carney, M R Pincus.   

Abstract

The tumor suppressor gene p53 has been identified as the most frequent target of genetic alterations in human cancers. Vinyl chloride, a known human carcinogen that induces the rare sentinel neoplasm angiosarcoma of the liver, has been associated with specific A-->T transversions at the first base of codons 249 and 255 of the p53 gene. These mutations result in an Arg-->Trp amino acid substitution at residue 249 and an Ile-->Phe amino acid substitution at residue 255 in a highly conserved region in the DNA-binding core domain of the p53 protein. To determine the effects of these substitutions on the three-dimensional structure of the p53 protein, we have performed molecular dynamics calculations on this core domain of the wild-type and the Trp-249 and Phe-255 mutants to compute the average structures of each of the three forms. Comparisons of the computed average structures show that both mutants differ substantially from the wild-type structure in certain common, discrete regions. One of these regions (residues 204-217) contains the epitope for the monoclonal antibody PAb240, which is concealed in the wild-type structure but accessible in both mutant structures. In order to confirm this conformational shift, tumor tissue and serum from vinyl chloride-exposed individuals with angiosarcomas of the liver were examined by immunohistochemistry and enzyme-linked immunosorbent assay. Individuals with tumors that contained the p53 mutations were found to have detectable mutant p53 protein in their tumor tissue and serum, whereas individuals with tumors without mutations and normal controls did not.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819013     DOI: 10.1007/bf01886863

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  16 in total

1.  Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library.

Authors:  C W Stephen; D P Lane
Journal:  J Mol Biol       Date:  1992-06-05       Impact factor: 5.469

2.  Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein.

Authors:  R Monaco; J M Chen; D Chung; P Brandt-Rauf; M R Pincus
Journal:  J Protein Chem       Date:  1995-08

Review 3.  Multifactorial analysis of p53 alteration in human cancer: a review.

Authors:  T Soussi; Y Legros; R Lubin; K Ory; B Schlichtholz
Journal:  Int J Cancer       Date:  1994-04-01       Impact factor: 7.396

4.  Expression of p21ras-related protein in the plasma and tissue of patients with adenomas and carcinomas of the colon.

Authors:  J C Luo; A I Neugut; G Garbowski; K A Forde; M Treat; S Smith; H Niman; P W Brandt-Rauf
Journal:  Biomarkers       Date:  1996       Impact factor: 2.658

Review 5.  The emerging picture of p53.

Authors:  H Selter; M Montenarh
Journal:  Int J Biochem       Date:  1994-02

6.  Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.

Authors:  P W Brandt-Rauf; R Monaco; M R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.

Authors:  J C Luo; A I Neugut; G Garbowski; K A Forde; M Treat; S Smith; W P Carney; P W Brandt-Rauf
Journal:  Cancer Lett       Date:  1995-05-08       Impact factor: 8.679

9.  Conformational effects of selected cancer-related amino acid substitutions in the p53 protein.

Authors:  P W Brandt-Rauf; I De Vivo; D C Dykes; M R Pincus
Journal:  J Biomol Struct Dyn       Date:  1992-10

10.  Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride.

Authors:  G E Trivers; H L Cawley; V M DeBenedetti; M Hollstein; M J Marion; W P Bennett; M L Hoover; C C Prives; C C Tamburro; C C Harris
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

View more
  6 in total

1.  Conformation-dependent phosphorylation of p53.

Authors:  V Adler; M R Pincus; T Minamoto; S Y Fuchs; M J Bluth; P W Brandt-Rauf; F K Friedman; R C Robinson; J M Chen; X W Wang; C C Harris; Z Ronai
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

2.  Conformational effects of a common codon 751 polymorphism on the C-terminal domain of the xeroderma pigmentosum D protein.

Authors:  Regina Monaco; Ramon Rosal; Michael A Dolan; Matthew R Pincus; Greg Freyer; Paul W Brandt-Rauf
Journal:  J Carcinog       Date:  2009

3.  Gene-environment interactions between DNA repair polymorphisms and exposure to the carcinogen vinyl chloride.

Authors:  Yongliang Li; Marie-Jeanne Marion; Jennifer Zipprich; Regina M Santella; Greg Freyer; Paul W Brandt-Rauf
Journal:  Biomarkers       Date:  2009-05       Impact factor: 2.658

4.  Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein.

Authors:  Regina Monaco; Ramon Rosal; Michael A Dolan; Matthew R Pincus; Paul W Brandt-Rauf
Journal:  Protein J       Date:  2007-12       Impact factor: 2.371

5.  Plastics and carcinogenesis: The example of vinyl chloride.

Authors:  Paul Wesley Brandt-Rauf; Yongliang Li; Changmin Long; Regina Monaco; Gopala Kovvali; Marie-Jeanne Marion
Journal:  J Carcinog       Date:  2012-03-12

6.  Computational screening and molecular dynamic simulation of breast cancer associated deleterious non-synonymous single nucleotide polymorphisms in TP53 gene.

Authors:  Kumaraswamy Naidu Chitrala; Suneetha Yeguvapalli
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.